Issoire (France), August 4, 2023 at 6:00 p.m. CEST – Following the announcement of the proposed acquisition of BIOCORP Production SA (FR0012788065 – ALCOR) (“BIOCORP”) by NOVO NORDISK (DK0060534915 – Novo-B), A leading global healthcare company headquartered in Denmark that develops treatments for diabetes and other chronic diseases (“NOVO NORDISK”), released on June 5, 2023, BIOCORP announces, continued obtaining the usual regulatory authorizations, the completion today of the off-market acquisition by NOVO NORDISK from BIO JAG, main shareholder of BIOCORP, as well as certain minority shareholders, including Nyenburgh, Greenstock and Vatel Capital, of a total of 2,838,669 shares representing 64.3% of the capital and 64.09% of the voting rights1 of BIOCORP, for a price of €35.00 per share (the “Control Block”).
The outstanding convertible bonds issued by BIOCORP have been fully redeemed in cash by BIOCORP as of the date hereof in connection with the completion of the acquisition of the Control Block.